Technical Analysis for BHVN - Biohaven Pharmaceutical Holding Company Ltd.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| See historical BHVN trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Expansion Breakout | Bullish Swing Setup | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Multiple of Ten Bullish | Other | 0.00% | |
| Above Upper BB | Strength | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| Stochastic Sell Signal | Bearish | 4.20% | |
| BB Squeeze Ended | Range Expansion | 4.20% | |
| Overbought Stochastic | Strength | 4.20% |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 09/27/2019
- Sector: Healthcare
- Industry: Biotechnology
Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates. Its pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity (NCE) that modulates glutamate, and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate (NMDA) receptor antagonism. Its clinical compound, trigriluzole, is indicated for neurodegenerative diseases and cancer indications, among others. Its pipeline also includes BHV-3000 and BHV-3500, which are in-licensed by the Company for a neurologic indication. It focuses on advancing other mechanistic approaches in orphan and neuroscience indications, and is exploring licenses for additional compounds.
Biopharmaceutical Cancer Drugs Chemical Compounds Organic Compounds Neuroscience Neurodegenerative Diseases Riluzole
Biopharmaceutical Cancer Drugs Chemical Compounds Organic Compounds Neuroscience Neurodegenerative Diseases Riluzole
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more BHVN news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 67.86 |
| 52 Week Low | 29.17 |
| Average Volume | 605,527 |
| 200-Day Moving Average | 48.1438 |
| 50-Day Moving Average | 45.3016 |
| 20-Day Moving Average | 47.1375 |
| 10-Day Moving Average | 47.909 |
| Average True Range | 1.9785 |
| ADX | 20.42 |
| +DI | 28.6235 |
| -DI | 13.3214 |
| Chandelier Exit (Long, 3 ATRs ) | 45.5645 |
| Chandelier Exit (Short, 3 ATRs ) | 49.6655 |
| Upper Bollinger Band | 50.1337 |
| Lower Bollinger Band | 44.1413 |
| Percent B (%b) | 1.16 |
| BandWidth | 12.712596 |
| MACD Line | 1.3546 |
| MACD Signal Line | 1.0588 |
| MACD Histogram | 0.2959 |
| Fundamentals | Value |
|---|---|
| Market Cap | 1.83 Billion |
| Num Shares | 35.8 Million |
| EPS | -7.54 |
| Price-to-Earnings (P/E) Ratio | -6.77 |
| Price-to-Sales | 0.00 |
| Price-to-Book | 5.62 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 54.89 | ||||
| Resistance 3 (R3) | 54.61 | 53.05 | 54.26 | ||
| Resistance 2 (R2) | 53.05 | 52.08 | 53.20 | 54.04 | |
| Resistance 1 (R1) | 52.07 | 51.48 | 52.56 | 52.35 | 53.83 |
| Pivot Point | 50.51 | 50.51 | 50.76 | 50.66 | 50.51 |
| Support 1 (S1) | 49.53 | 49.54 | 50.02 | 49.81 | 48.33 |
| Support 2 (S2) | 47.97 | 48.94 | 48.12 | 48.12 | |
| Support 3 (S3) | 46.99 | 47.97 | 47.91 | ||
| Support 4 (S4) | 47.27 |
